Skip Navigation


Rheumatology Advance Access originally published online on May 16, 2006
Rheumatology 2006 45(7):790-791; doi:10.1093/rheumatology/kel153
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
45/7/790    most recent
kel153v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kavanaugh, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kavanaugh, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Published by Oxford University Press on behalf of the British Society for Rheumatology 2006.

EDITORIAL

Pharmacoeconomic considerations in the treatment of psoriatic arthritis

"A cynic is someone who knows the cost of everything but the value of nothing." - Anonymous

A. Kavanaugh

Center for Innovative Therapy and Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, CA, USA.

Correspondence to: Arthur Kavanaugh, 9500 Gilman Drive La Jolla, CA 92093-0943, USA. E-mail: akavanaugh@ucsd.edu

The first 150 words of the full text of this article appear below.

In recent years, we have witnessed remarkable advances in the therapeutic approach to patients with various rheumatic diseases. Perhaps most notable has been the introduction of biological agents, particularly inhibitors of the key pro-inflammatory cytokine tumour necrosis factor-{alpha} (TNF-{alpha}). Initially, TNF-inhibitors were tested in patients with refractory, severe, established rheumatoid arthritis (RA). Data from many trials conclusively proved that in addition to dramatically improving the signs and symptoms of the disease, TNF-inhibitor therapy also enhanced functional status and quality of life and attenuated the progression of radiographic joint damage [1]. The remarkable success achieved by these agents has ‘raised the bar’ for the goals of therapy for RA. Currently, debate surrounds how best to define disease remission; until recently, such a goal was much more hypothetical than tangible. Following upon their success in refractory RA, TNF-inhibitors have been studied and proven to be highly effective in patients . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
I. Olivieri, S. de Portu, C. Salvarani, A. Cauli, E. Lubrano, A. Spadaro, F. Cantini, M. S. Cutro, A. Mathieu, M. Matucci-Cerinic, et al.
The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy
Rheumatology, August 24, 2008; (2008) ken320v1.
[Abstract] [Full Text] [PDF]